Clean Food Group: £4.5 Million Investment Led by Clean Growth Fund and New Agrarian April 14, 2026 Funding to accelerate scale-up of world-leading Knowsley fermentation facility
Kolibri Global Energy Inc. Provides Operations and Corporate Update April 13, 2026 Kolibri Global Energy Inc. (the “Company” or Kolibri”) (TSX: KEI, NASDAQ: KGEI) is pleased to provide an operations update on its upcoming wells in its Tishomingo field in Oklahoma and 2026 forecast based on the Company’s current drilling program. Operations & Corporate Update The Company has accelerated the timeline on its previously announced plan to [...]
Sumitomo Corporation, SMBC Aviation Capital, Apollo and Brookfield Complete the Acquisition of Air Lease Corporation April 8, 2026 Sumitomo Corporation, SMBC Aviation Capital, Apollo-managed funds (“Apollo”) and Brookfield today announced that they have completed the previously announced acquisition of Air Lease Corporation (“Air Lease”) and have renamed the business Sumisho Air Lease Corporation (“Sumisho Air Lease”). This transformational transaction improves the financial position of the business with long term support and aviation expertise [...]
No Layoffs, Salaries On Time: Danube Group Chairman Rizwan Sajan Assures Its 6000+ Workforce Despite Geopolitical Uncertainty April 6, 2026 At a time when the US–Israel–Iran conflict is reshaping geopolitical and economic realities, businesses across the region are being tested on their ability to adapt and endure. Against this backdrop, Danube Group’s Founder and Chairman Rizwan Sajan is setting a strong example of leadership by standing firmly by its workforce. This press release features multimedia. [...]
Prove Accelerates Global Innovation with Expansion of Ireland R&D Hub April 2, 2026 $5M investment and expanded Dublin team accelerates product strategy and supports Prove’s growing global customer base
Scottish AI and Software Development Firm Zudu Appoints New CEO and Moves Edinburgh HQ April 2, 2026 - New CEO Paul Duffy says big question for business leaders is do their companies have the delivery capability to close the AI gap - Zudu forecasting £5m revenue in current year and £10m by 2028
SecurityTech on the Rise: G+D Reports Strong Order Intake and High Resilience in 2025 April 2, 2026 In fiscal year 2025, Giesecke+Devrient (G+D) reaffirmed its position as global leader in SecurityTech for mission-critical infrastructure. In a market where security is becoming essential for technological and societal stability, G+D demonstrates strong growth prospects. In 2025, G+D achieved a record order intake of €3.6 billion (+8%). Revenue increased to €3.2 billion (+1%), although exchange [...]
Capitolis UK Approved to Operate an Organized Trading Facility (OTF) by the FCA March 31, 2026 Approval unlocks more optimization opportunities and efficiencies for clients and network
ECCEUKCH: The First Year of Activities to Promote European Extra Virgin Olive Oil in the UK and Switzerland Comes to a Close March 31, 2026 The first year of ECCEUKCH – The Excellence of European Olive Growing in the UK and Switzerland, the three-year information and promotion programme dedicated to high-quality European extra virgin olive oil, co-financed by the European Union under Regulation (EU) No 1144/2014, has come to an end. Promoted by the Tuscan Association of Olive Growers OL.MA. [...]
Alfasigma Reports Solid Performance in 2025 Supported by Double-Digit Revenue Growth in key strategic brands in Immunology (+17%1), Gastroenterology (+15%), Vascular (+10%), and Consumer Healthcare expansion portfolio in international markets March 31, 2026 Revenues of €1.8 billion (-4% versus PY) driven by solid performance across key therapeutic areas and global markets, partially offset by Ocaliva® withdrawal impact. Adjusted EBITDA2 of €350 million (-18% versus PY) underpinned by streamlined operational efficiencies and operating model evolution. Like-for-like Revenues up 7%, and EBITDA up 20%, adjusted for voluntarily withdrawal of Ocaliva® from US market. Marketing application under EMA review for the use of Jyseleca® in a new indication of axial spondyloarthritis (axSpA), a chronic inflammatory arthritis, to address unmet patient needs, submitted following the reporting period. Following the reporting period, agreement with GSK plc for worldwide exclusive rights to develop, manufacture and commercialise linerixibat; subsequently granted FDA approval for the US market (March 2026).